US generic sales pressure from competition
US generic sales declined due to additional competition on certain products, and recovery depends on resolving manufacturing compliance issues at several sites.
high · management_commentary
Sunpharma Ltd — Q3 FY26
Sun Pharma delivered a strong Q3 FY26 with consolidated revenue of INR 15,469 crore (+15.1% YoY) and EBITDA of INR 4,949 crore (+23.4% YoY), driven by broad-based growth in Indi...
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Proposed US Most Favored Nation pricing models
CMS proposed pricing models could impact US revenues; management declined to share mitigation strategies, citing commercial sensitivity.
medium · analyst_questionHigher effective tax rate impacting PAT growth
Effective tax rate rose to ~25% from ~15% last year, dampening PAT growth relative to EBITDA growth; expected to remain in that range.
medium · data_observationMilestone income may not recur
Management noted that milestone income of $55 million in Q3 may not recur in future quarters, potentially impacting revenue comparability.
low · management_commentary